Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Herba Desmodii Styracifolii flavonoids capsule is a botanical drug product derived from the total flavonoids extracted from *Desmodium styracifolium* (Osbeck) Merr., a plant widely used in Traditional Chinese Medicine (TCM) under the name Guang Jin Qian Cao. The capsule is primarily indicated for the treatment of urolithiasis, specifically to promote the clearance of kidney stones and reduce associated pain following ureteroscopic procedures. Its therapeutic effects are attributed to its ability to inhibit the formation, growth, and aggregation of calcium oxalate crystals, as well as its diuretic, anti-inflammatory, and antispasmodic properties. The drug is currently being evaluated in Phase 4 clinical trials in China to further establish its efficacy in promoting stone clearance and managing post-operative symptoms in patients with small residual fragments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on herba desmodii styracifolii flavonoids capsule.